Spina E - Search Results

1

Interaction between fluvoxamine and imipramine/desipramine in four patients.

Spina E, Campo GM, Avenoso A, Pollicino MA, Caputi AP. Spina E, et al. Ther Drug Monit. 1992 Jun;14(3):194-6. doi: 10.1097/00007691-199206000-00004. Ther Drug Monit. 1992. PMID: 1412604

2

Polymorphic debrisoquine oxidation and acute neuroleptic-induced adverse effects.

Spina E, Ancione M, Di Rosa AE, Meduri M, Caputi AP. Spina E, et al. Eur J Clin Pharmacol. 1992;42(3):347-8. doi: 10.1007/BF00266363. Eur J Clin Pharmacol. 1992. PMID: 1349529 No abstract available.

3

Debrisoquine oxidation phenotype and neuroleptic-induced dystonic reactions.

Spina E, Sturiale V, Valvo S, Ancione M, Di Rosa AE, Meduri M, Caputi AP. Spina E, et al. Acta Psychiatr Scand. 1992 Nov;86(5):364-6. doi: 10.1111/j.1600-0447.1992.tb03281.x. Acta Psychiatr Scand. 1992. PMID: 1485526

4

Debrisoquine oxidation phenotype during neuroleptic monotherapy.

Spina E, Martines C, Caputi AP, Cobaleda J, Piñas B, Carrillo JA, Benitez J. Spina E, et al. Eur J Clin Pharmacol. 1991;41(5):467-70. doi: 10.1007/BF00626371. Eur J Clin Pharmacol. 1991. PMID: 1684751

5

Debrisoquine oxidation in an Italian population: a study in healthy subjects and in schizophrenic patients.

Spina E, Campo GM, Calandra S, Caputi AP, Carrillo JA, Benitez J. Spina E, et al. Pharmacol Res. 1992 Jan;25(1):43-50. doi: 10.1016/s1043-6618(05)80063-5. Pharmacol Res. 1992. PMID: 1738757

6

Effect of phenobarbital on the pharmacokinetics of carbamazepine-10,11-epoxide, an active metabolite of carbamazepine.

Spina E, Martines C, Fazio A, Trio R, Pisani F, Tomson T. Spina E, et al. Ther Drug Monit. 1991 Mar;13(2):109-12. doi: 10.1097/00007691-199103000-00004. Ther Drug Monit. 1991. PMID: 2053116

7

No effect of thioridazine on plasma concentrations of carbamazepine and its active metabolite carbamazepine-10,11-epoxide.

Spina E, Amendola D'Agostino AM, Ioculano MP, Oteri G, Fazio A, Pisani F. Spina E, et al. Ther Drug Monit. 1990 Sep;12(5):511-3. doi: 10.1097/00007691-199009000-00017. Ther Drug Monit. 1990. PMID: 2293416

8

Diazepam treatment does not influence the debrisoquine or mephenytoin hydroxylation phenotyping tests.

Spina E, Buemi AL, Sanz E, Bertilsson L. Spina E, et al. Ther Drug Monit. 1989 Nov;11(6):721-3. doi: 10.1097/00007691-198911000-00019. Ther Drug Monit. 1989. PMID: 2595755

9

Debrisoquine oxidation in schizophrenic patients treated with neuroleptics.

Spina E, Buemi AL, Caputi AP, Benitez J, Cobaleda J, Garcia MA, Llerena A, Piña B. Spina E, et al. Pharmacol Res Commun. 1988 Dec;20(12):1103-4. doi: 10.1016/s0031-6989(88)80747-1. Pharmacol Res Commun. 1988. PMID: 2905478 No abstract available.

10

Evaluation of tricyclic antidepressant plasma levels by an automated enzyme immunoassay (EMIT) in comparison to a high-performance liquid chromatographic method.

Fazio A, Artesi C, Lorefice C, Oteri G, Romano F, Russo M, Spina E, Trio R, Pisani F. Fazio A, et al. Among authors: spina e. Ther Drug Monit. 1988;10(3):333-9. doi: 10.1097/00007691-198803000-00017. Ther Drug Monit. 1988. PMID: 3051537

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

414 results

Search Page

Filters